Brief: Santhera Announces Launch Of Early Access Program In China For Agamree By Its Partner Sperogenix
June 10 (Reuters) - Santhera Pharmaceuticals Holding AG
SANN.S :
* SANTHERA ANNOUNCES LAUNCH OF EARLY ACCESS PROGRAM IN CHINA
FOR
AGAMREE® BY ITS PARTNER SPEROGENIX
* SANTHERA PHARMACEUTICALS HOLDING AG - SUBJECT TO A
POSITIVE
REVIEW OUTCOME, APPROVAL COULD BE OBTAINED BY Q1-2025
Source text for Eikon: ID:nGNXb913Yg
Further company coverage: SANN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million